1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,021 | 0,025 | 11:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.03. | Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications | 195 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.03. | Genflow Biosciences - Issue of Equity & PDMR Notifications | 3 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Result of GM | 191 | ACCESS Newswire | Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.03. | Genflow Biosciences - Result of GM | 1 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Receipt of First Tranche of Grant | 230 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 02.03. | Genflow Biosciences - Receipt of First Tranche of Grant | 2 | RNS | ||
| 12.02. | Genflow meldet positive Zwischenergebnisse bei Gentherapie-Studie mit Hunden | 23 | Investing.com Deutsch | ||
| 12.02. | Genflow reports positive interim results from dog gene therapy trial | 1 | Investing.com | ||
| 12.02. | Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study | 199 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 12.02. | Genflow Biosciences - Preliminary Interim Results From Dog Study | - | RNS | ||
| 11.02. | Genflow Biosciences to seek approval for potential equity raise | 4 | Investing.com | ||
| 11.02. | Genflow Biosciences strebt Zustimmung für potenzielle Kapitalerhöhung an | - | Investing.com Deutsch | ||
| 11.02. | Genflow Biosciences PLC Announces Notice of GM | 220 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 11.02. | Genflow Biosciences - Notice of GM | - | RNS | ||
| 30.01. | Genflow Biosciences PLC Announces Holding(s) in Company | 280 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 28.01. | Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | 209 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION... ► Artikel lesen | |
| 28.01. | Genflow Biosciences - Administrative Approval of Grant & 2026 Priorities | - | RNS | ||
| 19.01. | EXECUTIVE CHANGES: Genflow Biosciences names Berdugo as new chair | 1 | Alliance News | ||
| 19.01. | Genflow Biosciences PLC Announces Directorate Change | 269 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 19.01. | Genflow Biosciences appoints new chairman to lead expansion | 2 | Investing.com |
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 40,800 | +0,99 % | Piper Sandler raises CRISPR Therapeutics price target on cash raise | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,150 | -4,48 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| DENALI THERAPEUTICS | 17,065 | -0,06 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,194 | -0,93 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| BIOAGE LABS | 18,200 | 0,00 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| LINEAGE CELL THERAPEUTICS | 1,370 | +2,24 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| BIOPHYTIS | 0,027 | +1,12 % | Biophytis and LynxKite expand alliance to boost AI-driven drug discovery | ||
| SERINA THERAPEUTICS | 2,040 | -5,56 % | Serina Therapeutics Shares Surge 70% On Private Placement | ||
| LONGEVERON | 1,110 | 0,00 % | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,170 | 0,00 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 30,050 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MAZE THERAPEUTICS | 49,430 | 0,00 % | Truist initiates Maze Therapeutics stock coverage with buy rating | ||
| TAYSHA GENE THERAPIES | 4,560 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate... ► Artikel lesen | |
| ARCELLX | 114,34 | -0,16 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ALX ONCOLOGY | 2,190 | 0,00 % | Wells Fargo initiates ALX Oncology stock with overweight rating |
Das Unternehmen GENFLOW BIOSCIENCES PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,004 (+20,00 %) liegt der Kurs bei 0,021 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.